Carlos Paya, M.D., Ph.D.
President and Chief Executive OfficerView Bio
Carlos Paya joined Immune Design in May 2011 as our President, Chief Executive Officer and director. He previously served as President of Elan Corporation, a pharmaceutical corporation, which was acquired by Perrigo Company, from November 2008 to April 2011. Before joining Elan Corporation, Dr. Paya was at Eli Lilly & Company, a pharmaceutical corporation, from September 2001 to November 2008, as Vice President, Lilly Research Laboratories. From January 1991 to August 2001, Dr. Paya was Professor of Medicine, Immunology, and Pathology, and Vice Dean of the Clinical Investigation Program at the Mayo Clinic in Rochester, Minnesota. He received his M.D. and Ph.D. degrees from the University of Madrid and underwent postdoctoral training at the Institute Pasteur, Paris, France.Close Bio
Stephen R. Brady, JD, LLM
Executive Vice President, Strategy & FinanceView Bio
Stephen R. Brady has been our Executive Vice President, Strategy & Finance since May 2015, and joined Immune Design in September 2013 as our Chief Business Officer. He previously served as Chief Business Officer for 3-V Biosciences, Inc., a biopharmaceutical company, from February 2011 to August 2013, and prior to that, he served as 3-V Bioscience, Inc.’s Vice President, Corporate Development, Strategy and Operations, from February 2010 to February 2011. From April 2007 to March 2010, he was at Proteolix, Inc., a biopharmaceutical company, most recently serving as Vice President, Corporate Development. Prior to Proteolix, Inc., Mr. Brady served as Senior Corporate Counsel at Lexicon Pharmaceuticals, Inc. from 2001 to 2007. Mr. Brady was also a Vice President with Lazard Venture Advisors, a division of Lazard Freres & Co. LLC, from 2000 to 2001, and an associate at Morrison & Foerster LLP from 1996 to 2000. Mr. Brady received a B.A. in English from the University of Oregon, a J.D. from the University of the Pacific and an LL.M. from New York University School of Law.Close Bio
Wayne Gombotz, Ph.D.
Chief Development OfficerView Bio
Wayne Gombotz joined Immune Design in December 2011 as our Chief Development Officer. He previously served as Vice President Pharmaceutical Operations at Omeros Corporation, a biopharmaceutical company, from May 2005 to October 2011. Before joining Omeros Corporation, Dr. Gombotz held several executive management positions including Vice President, Process Science & Pharmaceutical Development at Corixa Corporation, a biotechnology company, from September 2002 to March 2005 and Sr. Director, Analytical Chemistry and Formulation at Immunex Corporation, a biopharmaceutical company, from April 1993 to September 2002. He was also a staff scientist at Bristol-Myers Squibb and Enzytech Inc. Dr. Gombotz also currently serves as an Advisory Board Chair of the Center for Intracellular Delivery of Biologics and an Advisory Board Member for the University of Washington’s Department of Bioengineering. Dr. Gombotz received an M.S. and Ph.D. degree in Bioengineering from the University of Washington where he is an Affiliate Assistant Professor.Close Bio
Jan Henrik ter Meulen, M.D., Dr. habil., DTM&H
Chief Scientific OfficerView Bio
Jan Henrik ter Meulen joined Immune Design in October 2013 as our Chief Scientific Officer. He previously served as Executive Director of Vaccine Research and Head of Department of Vaccine Basic Research at Merck Research Laboratories, a pharmaceutical company, from April 2008 to September 2013. Prior to Merck, from March 2003 to April 2008, Dr. ter Meulen served as Executive Director Infectious Diseases at Crucell Holland and, from September 2006 to April 2008, as Chief Scientific Officer at Etna Biotech S.r.l., a subsidiary of Crucell. Dr. ter Meulen has an M.D. from Albert Ludwigs University Freiburg im Breisgau, a medical doctorate from Julius Maximilians University Wuerzburg, a higher doctorate from Philipps University Marburg, a Diploma in Tropical Medicine and Hygiene from the London School, and is a board certified in Clinical Microbiology by the Chambers of Physicians, Hamburg Germany.Close Bio
Frank J. Hsu, M.D.
Vice President, Head of OncologyView Bio
Frank Hsu joined Immune Design in October 2013 as Vice President, Head of Oncology. Dr. Hsu recently served as Chief Medical Officer for Zyngenia, Inc., where he was responsible for strategic planning and clinical development of multi-specific, multi-valent agents for the company’s lead programs in immune-mediated diseases and oncology. Prior to that, Dr. Hsu was Senior Medical Director at Genzyme in the Transplant and Oncology Division, where for more than nine years he was responsible for the clinical development of products in the areas of hematology, oncology, and stem cell transplant, and supported medical affairs and corporate development. From 1996-2003 he served as an Assistant Professor of Medicine in the Section of Oncology and as co-Director of the Immunology Research Program of the Yale Cancer Center. Dr. Hsu received his B.S. from Stanford University, his M.D. from Harvard Medical School, and his residency training in Internal Medicine at UCSF. He was a clinical and research fellow in Oncology at Stanford University from 1990-1996.Close Bio
Christopher Whitmore, CPA
Vice President, Finance and AdministrationView Bio
Chris Whitmore joined Immune Design in April 2015 and serves as our Vice President, Finance and Administration. Prior to joining Immune Design, he held various accounting and finance positions, most recently as Senior Director of Finance and Corporate Controller of AcelRx Pharmaceuticals, Inc., a publicly-traded specialty pharmaceutical company, from May 2011 to April 2015. From October 2008 to May 2011, he was at Sangamo BioSciences, a publicly-traded biopharmaceutical company, most recently serving as Corporate Controller. From October 2002 to May 2008, he was at KPMG, LLP, a global public accounting and professional services firm, most recently serving as Manager, Audit. Mr. Whitmore received a B.A. from the University of California at Santa Barbara. He received his Certified Public Accountant Certification from the state of California and currently holds an active license.Close Bio
Sergey Yurasov, M.D., Ph.D.
Senior Vice President, Clinical Development & Chief Medical OfficerView Bio
Sergey Yurasov joined Immune Design in October 2016 as Senior Vice President, Clinical Development and Chief Medical Officer. A board-certified, U.S. licensed hematologist/oncologist, Dr. Yurasov joined Immune Design from Clovis Oncology, where he most recently served as Senior Vice President, Clinical Development overseeing all clinical activities for its rociletinib, rucaparib and lucitanib programs, including regulatory approval and launch support for rociletinib and rucaparib. Prior to Clovis, Dr. Yurasov served as Associate Vice-President, Global Medicine Science, at ImClone Systems, a subsidiary of Eli Lilly & Co. where he led the development of ramucirumab culminating in the FDA submission for second line non-small cell lung cancer indication. He also served at Hoffman-La Roche as Clinical Director of Oncology, Pharma Research and Early Development. Prior to his industry experience, Dr. Yurasov was Assistant Professor of Clinical Investigation at Rockefeller University, where he was the principal investigator for NIH funded translational immunology research, and Clinical Instructor in the Department of Pediatrics at Memorial Sloan-Kettering Cancer Center, where he was an attending physician. Dr. Yurasov received his M.D. from the Russian State Medical University and his Ph.D. in medical sciences from the Research Institute for Pediatric Oncology in Moscow, Russia. He thereafter completed his residency in general pediatrics at Albert Einstein College of Medicine/Jacobi Medical Center and his subspecialty training in pediatric hematology/oncology at Memorial Sloan-Kettering Cancer Center while serving as a research fellow at The Rockefeller University in Dr. M. Nussenzweig’s laboratory.Close Bio